(Glibenclamide, glimepiride, and gliclazide) on proliferation and migration of vascular smooth muscle cells

Abstract

Background/Aims: and ischemia. Percutaneous transluminal angioplasty with or without stenting is the main therapeutic strategies; however, the restenosis rate is high in diabetics. Sulfonylureas (SUs) are widely prescribed agents for the treatment of type 2 diabetes (T2DM) and function by interacting with sulfonylurea receptors (SURs), which also exists in vascular smooth muscle migration of VSMCs play important roles in the formations of primary stenosis and restenosis, processes. Methods: Human aortic smooth muscle cells (HASMCs) were exposed to SUs prior to exposure to 30mM glucose. Cell proliferation was detected by CCK8 assay. Cell migration was detected by wound healing assay and transwell assay. Protein expression was determined by ATP channel in these processes. Results: contrast, above characteristics of HASMCs were apparently inhibited by gliclazide, and this was maintained after opening the KATP channel. Conclusion: These results imply that KATP channels play an important part in proliferation and migration of VSMCs induced by glibenclamide and potential for the prevention of vascular obstructive diseases in T2DM.